La Jolla Pharmaceutical Announces Positive Phase 2 Results of LJPC-401
On June 6, La Jolla Pharmaceutical Company (LJPC) announced positive clinical trial results from its Phase 2 study of LJPC-401. This was a pre-specified interim analysis of its synthetic human hepcidin in patients with hereditary hemochromatosis (HH). Patients experienced statistically significant efficacy levels and tolerated the drug well.
Sonal detected the news event and sent an alert at 9:00 am. Regular market trading opened for the day at $5.55. The market responded very well to the news, and LJPC’s stock price increased 84.5% throughout the day. The stock closed at $10.24.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!